3,148 Shares in Revolution Medicines, Inc. $RVMD Acquired by Temasek Holdings Private Ltd

Temasek Holdings Private Ltd bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,148 shares of the company’s stock, valued at approximately $251,000.

Several other large investors have also added to or reduced their stakes in RVMD. Indiana Trust & Investment Management Co acquired a new stake in Revolution Medicines during the fourth quarter worth approximately $32,000. Global Retirement Partners LLC grew its stake in Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after purchasing an additional 361 shares during the period. Torren Management LLC acquired a new stake in Revolution Medicines during the fourth quarter worth approximately $33,000. Arax Advisory Partners acquired a new stake in Revolution Medicines during the fourth quarter worth approximately $38,000. Finally, Darwin Wealth Management LLC acquired a new stake in Revolution Medicines during the fourth quarter worth approximately $40,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Insider Buying and Selling at Revolution Medicines

In other news, insider Mark A. Goldsmith sold 120,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total value of $18,010,800.00. Following the transaction, the insider owned 276,698 shares in the company, valued at $41,529,602.82. This trade represents a 30.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.60% of the stock is owned by corporate insiders.

Revolution Medicines Trading Up 4.0%

Shares of Revolution Medicines stock opened at $160.06 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.80 and a current ratio of 6.80. Revolution Medicines, Inc. has a 52 week low of $34.00 and a 52 week high of $166.50. The stock has a 50 day moving average price of $141.98 and a two-hundred day moving average price of $111.27. The stock has a market capitalization of $34.03 billion, a PE ratio of -22.64 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same quarter in the previous year, the business earned ($1.13) earnings per share. As a group, equities analysts anticipate that Revolution Medicines, Inc. will post -7.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Guggenheim raised their target price on Revolution Medicines to $205.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Evercore reissued an “outperform” rating on shares of Revolution Medicines in a research note on Tuesday, April 14th. Oppenheimer raised their price objective on Revolution Medicines from $165.00 to $195.00 and gave the company an “outperform” rating in a research note on Monday, June 1st. Finally, HC Wainwright raised their price objective on Revolution Medicines from $169.00 to $195.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $123.72.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.